Search Clinical Trials in the EU

Duration

Visits

Phase

Oral

Benefits

Drugs

Locations

Clinical Specialty

1641-1660 of 1,694 trials

Diabetic Macular Edema: BI 1815368 Study

We are testing whether the oral medication BI 1815368 can improve vision in people with diabetic macular edema. The study will also look at the safety of this treatment over time.

Diabetic Macular Edema6-12 monthsEfficacy phase (II)11-15 visits Investigational Medicines Partially RemoteEndocrinologyOphthalmology

Advanced Solid Tumors: EIK1004 Treatment Study

We are testing a new treatment called EIK1004 for people with advanced solid tumors to see how safe it is and if it may help reduce tumor activity. This study will help us understand the best dose and its effects.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Spinocerebellar Ataxia SCA27B: Fampridine Study

We are investigating whether fampridine can help improve movement and daily activities in patients with spinocerebellar ataxia SCA27B. This study will also assess its effects on quality of life and overall health.

Spinocerebellar Ataxia1-2 yearsConfirmation phase (III)≤5 visits Standard MedicinesInternal MedicineNeurology

Cemiplimab for Advanced Adrenocortical Cancer

We are studying whether cemiplimab can help patients with advanced adrenocortical cancer maintain their health after initial treatment. This trial focuses on those who have not experienced disease progression.

Adrenocortical Carcinoma>2 yearsEfficacy phase (II)No Placebo Standard MedicinesOncology

Chronic Obstructive Pulmonary Disease: AZD6793 Tablets

We are investigating whether AZD6793 can help reduce flare-ups in adults with moderate to very severe COPD. The study will also look at its effects on lung function and overall health.

Chronic Obstructive Pulmonary Disease (COPD)6-12 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Partially RemotePulmonology

Heart Disease: AZD0780 Medication Study

We are testing whether AZD0780 can help reduce serious heart and vascular problems in patients with existing heart disease or those at high risk. This study compares AZD0780 to a placebo to see which is more effective.

Atherosclerotic Cardiovascular DiseaseConfirmation phase (III)6-10 visits Investigational MedicinesCardiologyInternal Medicine

High 'Bad' Cholesterol: AZD0780 Study

We are investigating how well AZD0780 works for adults with high LDL cholesterol and heart disease or at risk for it. The goal is to see if it can lower cholesterol levels more effectively than a placebo.

High CholesterolAtherosclerotic Cardiovascular Disease1-2 yearsConfirmation phase (III)6-10 visits Investigational MedicinesCardiologyInternal Medicine

Kidney Transplant: Reduced Immunosuppression for Older Adults

We are studying whether a lower dose of immunosuppressive medication is as effective and safe as the standard dose for older adults after kidney transplantation. This may help improve their overall health and quality of life.

End-stage Renal Disease1-2 yearsMonitoring phase (IV)6-10 visits No Placebo Standard MedicinesInternal MedicineNephrology

Major Depressive Disorder: NBI-1065845 Treatment Study

We are evaluating a new medication to see if it helps maintain improvement in people with Major Depressive Disorder. This study looks at its effects on depressive symptoms and overall functioning.

Major Depressive DisorderConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemotePsychiatry

Glioblastoma: Intraoperative Photodynamic Therapy with Pentalafen®

We are studying a new light-based treatment for adults with grade IV glioblastoma during surgery. The goal is to evaluate its safety and how well it works in reducing tumor response.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visits No Placebo Standard MedicinesNeurologyOncology

Advanced Breast Cancer: PF-07248144 with Fulvestrant

We are studying a new treatment combining PF-07248144 and fulvestrant for adults with hormone receptor-positive, HER2-negative advanced breast cancer. This trial aims to see if it helps patients whose cancer has progressed after prior therapy.

Hormone Receptor-Positive, HER2-Negative Breast CancerConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Breast Cancer: Patritumab Deruxtecan vs. Standard Treatment

We are studying a new medication for patients with hormone receptor-positive, HER2-negative advanced breast cancer. The goal is to see if it works better than the current treatment options.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteGynecology and ObstetricsOncology

HIV-1 Prevention: MK-8527 Oral Medication

We are studying a new once-monthly pill, MK-8527, to see if it can effectively prevent HIV-1 infection compared to a daily treatment. The trial will also assess how safe and tolerable this new medication is for participants.

HIV-1>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Partially RemoteInfectious DiseasesInternal Medicine

Alzheimer's Disease: KarXT + KarX-EC Treatment

We are studying a new combination treatment for agitation in people with Alzheimer's disease. The goal is to see if it can reduce agitation symptoms better than a placebo.

Alzheimer's Disease Agitation3-6 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPsychiatry

Ulcerative Colitis: SAR441566 Study

We are investigating the effects of SAR441566 in adults with moderate-to-severe ulcerative colitis. The study aims to see if different doses can help achieve remission and improve overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Primary Aldosteronism: Baxdrostat Study

We are investigating how safe and effective baxdrostat is for adults with primary aldosteronism. The goal is to see if it can improve blood pressure and other health measures compared to a placebo.

Primary Hyperaldosteronism1-2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Investigational Medicines Partially RemoteCardiologyEndocrinologyInternal Medicine

Advanced Colorectal Cancer: OMTX705 Combination Therapy

We are studying a new drug, OMTX705, combined with regorafenib and tislelizumab for patients with advanced colorectal cancer. The goal is to evaluate its safety and effectiveness in those who have not responded to previous treatments.

Metastatic Colorectal Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Alzheimer’s Disease: KarXT + KarX-EC Treatment

We are studying a new treatment for cognitive impairment in people with mild to moderate Alzheimer’s disease. The trial will check if it helps improve thinking skills and daily activities, while also ensuring safety.

Mild to Moderate Alzheimer's Disease1-2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Investigational MedicinesNeurologyPsychiatry

Inflammatory Rheumatic Diseases: JAK Inhibitor Dose Reduction Study

We are exploring if lowering the dose of JAK inhibitors is as effective as keeping the current dose for patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis in low disease activity. This study will also look at safety and how many patients can successfully reduce their medication.

Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis1-2 yearsMonitoring phase (IV)6-10 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Tonsillectomy Pain Relief: Ropivacaine vs. Lidocaine

We are comparing two local anesthetics to see which one better reduces pain after tonsillectomy. This study aims to find the most effective option for managing postoperative discomfort.

Chronic Tonsillitis6-12 monthsMonitoring phase (IV)No Placebo Standard MedicinesOtolaryngology

Search Clinical Trials in the European Union